March 5, 2008 – Combining PET and CT for radiation therapy treatment planning in head and neck carcinoma patients provides local and regional disease control in comparison to CT alone, said a study in the March 1 issue of the International Journal for Radiation Oncology Biology Physics, the official journal of the American Society for Therapeutic Radiology and Oncology.

This study was conducted to calculate the clinical outcomes, including overall survival, disease-free survival and the incidence of recurrence of patients receiving PET/CT-guided radiation therapy and the correlation of the clinical outcomes to the maximum standard uptake value obtained on the PET scan.

According to the study, between Dec. 2002 and Aug. 2006, 42 patients with a median age of 55, who were diagnosed with head and neck squamous cell carcinoma, were given PET/CT imaging as part of their radiation therapy planning. The patients were monitored for at least six months following their treatment, with a mean follow-up time of 32 months.

Overall survival of the 42 study patients was 82.8 percent at two years and 74.1 percent at three years, superior to the survival rate that was found in a Radiation Therapy Oncology Group study in which patients received standard fractionation or accelerated fractionation with concomitant boost, said the study.

Results found that disease free survival for the 42 study patients was 71 percent and 66.9 percent at two and three years respectively. The cumulative incidence of recurrence was 18.7 percent. The study also found that standard uptake value quality predictor of local recurrence and that dose escalation based on standard uptake value is unlikely to be a fruitful treatment strategy, said the organization.

CT has been the go to decision for treatment planning for head and neck squamous cell carcinomas, but PET is proven to have an advantage over CT and other imaging modalities for primary tumor detection, including involved lymph nodes and distant metastatic disease not clearly otherwise identified. Using solely PET does have several disadvantages though, such as poor correlation to precise anatomic structures, but these negative impacts are reduced when PET and CT are combined by fusing the separate scans taken on a hybrid scanner.

For more information: www.astro.org


Related Content

News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | PET Imaging

June 18, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 18, 2024
arrow
News | PET Imaging

June 14, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 14, 2024
arrow
News | FDA

June 10, 2024 — Siemens Healthineers announces the Food and Drug Administration clearance of the Biograph Trinion, a ...

Time June 10, 2024
arrow
News | Radiology Business

May 14, 2024 — University Hospitals (UH) and Siemens Healthineers announce a 10-year strategic alliance that builds on ...

Time May 14, 2024
arrow
News | Cardiac Imaging

April 23, 2024 — CDL Nuclear Technologies, a pioneer in advanced diagnostic solutions, is proud to announce the launch ...

Time April 23, 2024
arrow
News | FDA

January 23, 2024 — Siemens Healthineers announces the Food and Drug Administration (FDA) clearance of syngo Virtual ...

Time January 23, 2024
arrow
News | Artificial Intelligence

January 23, 2024 — Quibim announced it has added an industry-leading cancer detection capability to its prostate tool ...

Time January 22, 2024
arrow
News | Radiology Business

December 27, 2023 — The American Roentgen Ray Society (ARRS) announced David M. Naeger, MD, as the 2024 ARRS ...

Time December 27, 2023
arrow
News | Radiopharmaceuticals and Tracers

December 6, 2023 — Philochem AG, a wholly owned subsidiary of Philogen S.p.A., and Blue Earth Diagnostics, a Bracco ...

Time December 06, 2023
arrow
Subscribe Now